Drug Profile
Research programme: HIV infections therapeutics - Intarcia Therapeutics
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Intarcia Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections